Effect of a new inhibitor of the synthesis of 20-HETE on cerebral ischemia reperfusion injury

Stroke

Volumn 37, Issue 5, 2006, Pages 1307-1313

  Omura, Tomohiro ^a,d   Tanaka, Yu ^a   Miyata, Noriyuki ^a   Koizumi, Chie ^a   Sakurai, Takanobu ^a   Fukasawa, Misako ^a   Hachiuma, Kenji ^a   Minagawa, Toshiya ^a   Susumu, Teruo ^b   Yoshida, Shigeru ^a   Nakaike, Shiro ^a   Okuyama, Shigeru ^a   Harder, David R ^c   Roman, Richard J ^c  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

^b SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d NONE   (Japan)

Author keywords

20 HETE; Brain injury; Cytochrome P450; Ischemic stroke

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ARACHIDONIC ACID; CYTOCHROME P450 4A; MORPHOLINE DERIVATIVE; N (3 CHLORO 4 MORPHOLIN 4 YL)PHENYL N' HYDROXYIMIDOFORMAMIDE; TISSUE PLASMINOGEN ACTIVATOR; TS 011; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; INTERNAL CAROTID ARTERY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MONKEY; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; STROKE; THROMBOEMBOLISM;

ANIMALS; BRAIN ISCHEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FORMAMIDES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HAPLORHINI; HYDROXYEICOSATETRAENOIC ACIDS; MALE; MORPHOLINES; RATS; RATS, WISTAR; REPERFUSION INJURY;

EID: 33646707830     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000217398.37075.07     Document Type: Article

References (27)

1. Ginsberg MD. Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection. Stroke. 2003;34:214-223.
2. The National Institute of Neurological Disorder and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Eng J Med. 1995;333:1581-1587.
3. Pilitsis JG, Coplin WM, O'Regan MH, Wellwood JM, Diaz FG, Fairfax MR, Michael DB, Phillis JW. Measurement of free fatty acids in cerebrospinal fluid from patients with hemorrhagic and ischemic stroke. Brain Res. 2003;985:198-201.
4. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 2002;82:131-185.
5. Harder DR, Gebremedhin D, Narayanan J, Jefcoat C, Falck JR, Campbell WB, Roman R. Formation and action of a P-450 4A metabolite of arachidonic acid in cat cerebral microvessels. Am J Physiol. 1994;266:H2098-H2107.
6. Alonso-Galicia M, Sun CW, Falck JR, Harder DR, Roman RJ. Contribution of 20-HETE to the vasodilator actions of nitric oxide in renal arteries. Am J Physiol. 1998;275:F370-F378.
7. + channel of the rat thick ascending limb. Clin Invest. 1999;103:963-970.
8. Oyekan A, Balazy M, McGiff JC. Renal oxygenases: differential contribution to vasoconstriction induced by ET-1 and Ang II. Am J Physiol. 1997;273:R293-R300.
9. Kehl F, Cambj-Sapunar L, Maier KG, Miyata N, Kametani S, Okamoto H, Hudetz AG, Schulte ML, Zagorac D, Harder DR, Roman RJ. 20-HETE contributes to the acute fall in cerebral blood flow after subarachnoid hemorrhage in the rat. Am J Physiol Heart Circ Physiol. 2002;282:H1556-H1565.
10. Cambj-Sapunar L, Yu M, Harder DR, Roman RJ. Contribution of 5-hydroxytryptamine 1B receptors and 20-hydroxyeiscosatetraenoic acid to fall in cerebral blood flow after subarachnoid hemorrhage. Stroke. 2003;34:1269-1275.
11. Poloyac SM, Reynolds RB, Yonas H, Kerr ME. Identification and quantification of the hydroxyeicosatetraenoic acids, 20-HETE and 12-HETE, in the cerebrospinal fluid after subarachnoid hemorrhage. J Neurosci Methods. 2005;144:257-263.
12. Yu M, Cambj-Sapunar L, Kehl F, Maier KG, Takeuchi K, Miyata N, Ishimoto T, Reddy LM, Falck JR, Gebremedhin D, Harder DR, Roman RJ. Effects of a 20-HETE antagonist and agonists on cerebral vascular tone. Eur J Pharmacol. 2004;486:297-306.
13. Takeuchi K, Renic M, Bohman QC, Harder DR, Miyata N, Roman RJ. Reversal of delayed vasospasm by an inhibitor of the synthesis of 20-HETE. Am J Physiol Heart Circ Physiol. 2005;289:H2203-H2211.
14. Hacein-Bey L, Harder DR, Meier HT, Varelas PN, Lauer KK, Cusick JF, Roman RJ. Improvement in angiographic vasospasm with a 20-HETE enzyme inhibitor in a subarachnoid hemorrhage dog model. Am Soc Neurorad. 2006;In press.
15. Miyata N, Seki T, Tanaka Y, Omura T, Taniguchi K, Doi M, Bandou K, Kametani S, Sato M, Okuyama S, Cambj-Sapunar L, Hudetz A, Shulte ML, Harder DR, Roman RJ. Benefical effects of a new 20-HETE synthesis inhibitor, TS-011, on hemorrhagic and ischemic stroke. J Pharmacol Exp Ther. 2005;314:77-85.
16. Nagasawa H, Kogure K. Correlation between cerebral blood flow and histologic changes in a new rat model of middle cerebral artery occlusion. Stroke. 1989;20:1037-1043.
17. Belayev L, Alonso OF, Busto R, Zhao W, Ginsberg MD. Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model. Stroke. 1996;27:1616-1622.
18. De Ryck M, Van Reempts J, Borgers M, Wauquier A, Janssen PA. Photochemical stroke model: flunarizine prevents sensorimotor deficits after neocortical infarcts in rats. Stroke. 1989;20:1383-1390.
19. Kito G, Nishimura A, Susumu T, Nagata R, Kuge Y, Yokota C, Minematsu K. Experimental thromboembolic stroke in cynomolgus monkey. J Neurosci Methods. 2001;105:45-53.
20. Dawson DA, Sugano H, McCarron RM, Hallenbeck JM, Spatz M. Endothelin receptor antagonist preserves microvascular perfusion and reduces ischemic brain damage following permanent focal ischemia. Neurochem Res. 1999;24:1499-1505.
21. Shiino A, Matsuda M, Susumu T, Handa J. Effects of the calcium antagonist nilvadipine on focal cerebral ischemia in spontaneously hypertensive rats. Surg Neurol. 1991;35:105-110.
22. Zhao Z, Cheng M, Maples KR, Ma JY, Buchan AM. NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat. Brain Res. 2001;909:46-50.
23. Bochelen D, Rudin M, Sauter A. Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury. J Pharmacol Exp Ther. 1999;288:653-659.
24. Takagi K, Sato T, Shirasaki Y, Narita K, Tamura A, Sano K. Post-ischemic administration of DY-9760e, a novel calmodulin antagonist, reduced infarct volume in the permanent focal ischemia model of spontaneously hypertensive rat. Neurol Res. 2001;23:662-668.
25. Nagayama M, Niwa K, Nagayama T, Ross ME, Iadecola C. The cyclooxygenase-2 inhibitor NS-398 ameliorates ischemic brain injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene. J Cereb Blood Flow Metab. 1999;19:1213-1219.
26. Mori E, Ember J, Copeland BR, Thomas WS, Koziol JA, del Zoppo GJ. Effect of trilazad mesylate on middle cerebral artery occlusion/reperfusion in non-human primates. Cerebrovasc Dis. 1995;5:342-349.
27. Rosolowsky M, Falck JR, Campbell WB. Metabolism of arachidonic acid by canine polymorphonuclear leukocytes synthesis of lipoxygenase and omega-oxidized metabolites. Biochim Biophys Acta. 1996;1300:143-150.